Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem, +17

The Lancet Oncology

Surgical OncologyGastrointestinal OncologyMedicinePaclitaxel Versus PlaceboGastroenterology +5

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, +15

The Lancet

MedicineMetronomic TherapyPhase Iii TrialBronchial NeoplasmCancer Treatment +5

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

Michael Emig, Susanne Saußele, H Wittor, +6

Leukemia

Residual DiseaseEngineeringMedicineBiomedical ImagingPathology +7

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Andreas Hochhaus, Andreas Reiter, Anja Reichert Susanne Saußele, +9

Blood

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Robert Pirker, A. Szczęsna, Joachim von Pawel, +7

Journal of Clinical Oncology

Cancer ManagementImmunologyPathologyFirst-line TreatmentOncology +17

Loss of <i>p53</i> impedes the antileukemic response to BCR-ABL inhibition

Hans‐Guido Wendel, Elisa de Stanchina, Enriqué Cepero, +10

Proceedings of the National Academy of Sciences

Hematological MalignancyTumor BiologyMedicineImmunologyTumor Immunity +12

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).

H. Wilke, Eric Van Cutsem, Sang Cheul Oh, +13

Journal of Clinical Oncology

Esophageal CancerImmunologyGastroenterologyPathologyGastric Adenocarcinoma +16

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

Kohei Shitara, Kei Muro, Yasuhiro Shimada, +20

Gastric Cancer

Gastrointestinal OncologyMedicineGastroenterologyClinical TrialsPathology +9

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma

Salah‐Eddin Al‐Batran, Eric Van Cutsem, Sang Cheul Oh, +14

Annals of Oncology

Fractalkine-upregulated milk-fat globule EGF factor-8 protein in cultured rat microglia

Fernando Leonardi‐Essmann, Michael Emig, Yoshihisa Kitamura, +2

Journal of Neuroimmunology

InflammationEpendymaCultured Rat MicrogliaMedicineImmunology +8